熱門資訊> 正文
Nuvectis Pharma GAAP每股收益为0.27美元
2025-05-06 23:18
- Nuvectis Pharma press release (NASDAQ:NVCT): GAAP EPS of $0.27.
- Cash and cash equivalents were $29.9 million as of March 31, 2025, compared to $18.5 million as of December 31, 2024.
More on Nuvectis Pharma
- Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
- Nuvectis Pharma announces pricing of $13.5M public offering
- Seeking Alpha’s Quant Rating on Nuvectis Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
